New G-CSF agonists for neutropenia therapy
Authors:
- 27 September 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 23 (1) , 21-35
Abstract
Introduction: Granulocyte colony-stimulating factor (G-CSF; filgrastim) and its pegylated form (pegfilgrastim) are widely used to treat neutropenia associated with myelosuppressive chemotherapy and bone marrow transplantation, AIDS-associated or drug-induced neutropenia, and neutropenic diseases. G-CSF facilitates restoration of neutrophil counts, decreases incidence of infection/febrile neutropenia and reduces resource utilization. G-CSF is also widely used to mobilize peripheral blood stem cells for hematopoietic transplant. Areas covered: We review the therapeutic use, cost effectiveness and disease impact of G-CSF for neutropenia, development of G-CSF biosimilars and current next-generation discovery efforts. Expert opinion: G-CSF has impacted the treatment and survival of patients with congenital neutropenias. For chemotherapy-associated neutropenia, cost effectiveness and impact on survival are still unclear. G-CSFs are expensive and require systemic administration. Market entry of new biosimilars, some with enhanced half-life profiles, will probably reduce cost and increase cost effectiveness. There is no evidence that marketed or late development biosimilars display effectiveness superior to current G-CSFs. Second-generation compounds that mimic the activity of G-CSF at its receptor, induce endogenous ligand(s) or offer adjunct activity have been reported and represent attractive G-CSF alternatives, but are in preclinical stages. A significant therapeutic advance will require reduced depth and duration of neutropenia compared to current G-CSFs.Keywords
This publication has 124 references indexed in Scilit:
- G-CSF receptor mutations in patients with congenital neutropeniaCurrent Opinion in Hematology, 2008
- Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilizationBlood, 1994
- Proliferative but not nonproliferative responses to granulocyte colony- stimulating factor are associated with rapid activation of the p21ras/MAP kinase signalling pathwayBlood, 1994
- Differentiation and proliferation of hematopoietic stem cellsBlood, 1993
- Assignment of the human granulocyte colony-stimulating factor receptor gene (CSF3R) to chromosome 1 at region p35–p34.3Genomics, 1991
- Human granulocyte colony-stimulating factor specifically binds to murine myeloblastic NFS-60 cells and activates their guanosine triphosphate binding proteins/adenylate cyclase systemBlood, 1989
- Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patientsBlood, 1988
- Human Pluripotent Hemopoietic Colony Stimulating Factor: Activities on Human and Murine CellsImmunobiology, 1986
- Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid CellsScience, 1986
- Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.Proceedings of the National Academy of Sciences, 1985